Precision Medical Research of Non-immune Fetal Hydrops (NIFH)-From Prenatal Diagnosis to Intrauterine Treatment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02956564 |
Recruitment Status : Unknown
Verified November 2016 by Shanghai First Maternity and Infant Hospital.
Recruitment status was: Not yet recruiting
First Posted : November 6, 2016
Last Update Posted : December 12, 2016
|
Sponsor:
Shanghai First Maternity and Infant Hospital
Information provided by (Responsible Party):
Shanghai First Maternity and Infant Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Based on multi-center clinical research resources, a large-scale prospective cohort study will be conduted to make a more accurate diagnosis and intervention plan of Non-immune fetal hydrops (NIFH), and then establish NIFH accurate treatment strategy which is suitable for China's national conditions.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Fetal Hydrops | Procedure: intrauterine intervention | Not Applicable |
-
Etiological study of Non-immune fetal hydrops(NIFH):
- Etiological study of NIFH in mid-pregnancy period;
- Etiological study of NIFH and hygroma colli in first trimester;
- Value assessment of technology for exome sequencing in diagnosis of NIFH;
-
The accuracy of NIFH intrauterine intervention and its effect assessment:
- Perinatal outcomes of NIFH ;
- The effect of intrauterine treatments.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 144 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Precision Medical Research of Non-immune Fetal Hydrops (NIFH)-From Prenatal Diagnosis to Intrauterine Treatment |
Study Start Date : | December 2016 |
Estimated Primary Completion Date : | August 2018 |
Estimated Study Completion Date : | August 2018 |
Resource links provided by the National Library of Medicine

Arm | Intervention/treatment |
---|---|
exposure group
subjects in this group are those who accept intrauterine intervention
|
Procedure: intrauterine intervention
choose different surgeries according to different causes |
No Intervention: control group
subjects in this group are those who do not accept intrauterine intervention
|
Primary Outcome Measures :
- Neonatal mortality [ Time Frame: 1 year ]
Secondary Outcome Measures :
- Success rate for the operation [ Time Frame: 1 week ]
Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Cases corresponding to diagnosis standards
- Willing to accept the regular follow-up
Exclusion Criteria:
- Immune hydrops fetalis
- Multiple pregnancy, except for twin-to-twin transfusion syndrome IV
No Contacts or Locations Provided
Responsible Party: | Shanghai First Maternity and Infant Hospital |
ClinicalTrials.gov Identifier: | NCT02956564 |
Other Study ID Numbers: |
ShanghaiFMIH-FMU1 |
First Posted: | November 6, 2016 Key Record Dates |
Last Update Posted: | December 12, 2016 |
Last Verified: | November 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Additional relevant MeSH terms:
Hydrops Fetalis Edema Erythroblastosis, Fetal Fetal Diseases Pregnancy Complications Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases |
Hematologic Diseases alpha-Thalassemia Thalassemia Hemoglobinopathies Genetic Diseases, Inborn Immune System Diseases |